The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma

Lung Cancer

Volumn 69, Issue 2, 2010, Pages 187-193

  Casali, Christian ^a   Cucca, Marina ^a   Rossi, Giulio ^a   Barbieri, Fausto ^a   Iacuzio, Laura ^a   Bagni, Bruno ^a   Morandi, Uliano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Non Small Cell Lung Cancer; Positron emission tomography; Prognosis; Standardized Uptake Value; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 77954145845     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.10.015     Document Type: Article

References (30)

1. Alberg A.J., Ford J.G., Samet M.J. Epidemiology of lung cancer. ACCP Evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:29S-55S.
2. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26(21):552-559.
3. Pisters K.M., Evans W.K., Azzoli C.G., et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer Guideline. J Clin Oncol 2007, 25:5506-5518.
4. Scott W.J., Howington J., Feigenberg S., et al. Treatment of non-small cell lung cancer stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
5. Brundage D.M., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer. A decade of progress. Chest 2002, 122(3):1037-1057.
6. van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359:1388-1393.
7. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343:254-261.
8. Duhaylongsod F.G., Lowe V.J., Patz E.F., et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995, 60:1348-1352.
9. Patz E.F., Connolly J., Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol 2000, 174:769-774.
10. Higashi K., Ueda Y., Arisaka Y., et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002, 43:39-45.
11. Ohtsuka T., Nomori H., Watanabe K., et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006, 107:2468-2473.
12. Goodgame B., Pillot G.A., Yang Z., et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008, 3:130-134.
13. Hanin F.X., Lonneux M., Cornet J., et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33:819-823.
14. Cerfolio R.J., Bryant A.S., Ohja B., et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
15. Al-Sarraf, Gately K., Lucey J., et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothoracic Surg 2008, 34:892-897.
16. Kim R.H., Kim D.J., Lee W.W., et al. The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. Eur J Cardiothoracic Surg 2009, 35:712-717.
17. Van Baardwijk A., Dooms C., Van Suylen R.J., et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1a and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007, 43:1392-1398.
18. Vesselle H., Freeman J.D., Wiens L., et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007, 13(11):3255-3263.
19. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
20. Sasaki R., Komaki R., Macapinlac H. SUV by FDG-PET predicts outcomes of NSCLC. Int J Radiat Oncol Biol Phys 2003, 57(Suppl. 2):S166.
21. Dhital K., Saunders C.A.B., Seed P.T., et al. 18F-fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000, 18:425-428.
22. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. Prognostic importance of the standardized uptake value on (18) F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999, 10:3201-3206.
23. Hoang J.K., Hoagland L.F., Coleman R.E., et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage nonsmall-cell lung carcinoma. J Clin Oncol 2008, 26:1459-1464.
24. Xu X., Yu J., Sun X., et al. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III non-small cell lung cancer. Am J Clin Oncol 2008, 31:470-475.
25. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
26. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111(6):1710-1717.
27. Kim C.K., Gupta N.C., Chandramouli B., et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994, 35:164-167.
28. Tumours of the lung, pleura, thymus and heart. Pathology and genetics. WHO classification of tumours 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
29. Lee J.R., Madsen M.T., Bushnel D., et al. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000, 21:685-690.
30. William W.N., Lin H.Y., Lee J.J., et al. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136:701-709.